7 / 18
Page 24
Notes:
allied
academies
Ann Clin Trials Vaccines Res. 2017 | Volume 1 Issue 2
Global Vaccines & Vaccination Summit & B2B
November 01-02, 2017 | Toronto, Canada
Tumor liberated protein (TLP) as potential vaccine for lung cancer patients
Giulio Tarro
Foundation de Beaumont Bonelli for cancer research, Italy
T
umor liberated protein (TLP) has been previously described
as a TAA (complex) present in the sera from lung cancer
patients with early stage disease. Since early detection
improves overall survival in lung cancer, identification of
screening biomarkers for patients at risk for the development
of this disease represents an important target. Starting from
the peptide epitope RTNKEASI previously isolated from TLP
complexes, we generated a rabbit anti-RTNKEASI serum. This
antiserum detected and immunoprecipitated a 55kDa protein
band in the lysate of the lung cancer cell line A549. This protein
band was identified as aldehyde dehydrogenase isoform 1A1
throughmass spectrometry, revealing themolecular nature of at
least one component of the previously described TLP complex.
Next, we screened a cohort of 29 lung cancer patients (all
histologies), 17 patients with non-neoplastic lung pathologies
and 9 healthy donors for the presence of serum ALDH1A1 and
global serum ALDH by enzyme-linked immunosorbent assay.
This analysis indicated that the presence of ALDH was highly
restricted to patients with lung cancer. Interestingly, the global
ALDH test detected more lung cancer patients compared to the
ALDH1A1-specific test, suggesting that other ALDH isoforms
might add to the sensitivity of the assay. Our data suggest that
ALDH levels may therefore be evaluated as part of a marker
panel for lung cancer screening. Finally, the ability of the
immune system to recognize a TAA, enables the development of
a vaccine approach for preventive and therapeutic application
and represents a main target of this field of research.
Speaker Biography
Giulio Tarro has graduated from Medicine School, Naples University (1962). He
was Research Associate at Division of Virology and Cancer Research, Children’s
Hospital (1965-1968), Assistant Professor of Research Pediatrics, College Medicine
(1968-1969), Cincinnati University, Ohio, Oncological Virology Professor, Naples
University (1972-1985). He acted as Chief Division Virology (1973-2003), Head
Department Diagnostic Laboratories, (2003-2006), D. Cotugno Hospital for Infectious
Diseases, Naples; Emeritus, 2006. Since 2007, he is the Chairman Committee of
Biotechnologies and VirusSphere, World Academy Biomedical Technologies, UNESCO,
Adjunct Professor Department Biology, Temple University, College of Science and
Technology, Philadelphia, Recipient of the Sbarro Health Research Organization
lifetime achievement award (2010). His researches have been concerned with the
characterization of specific virus-induced tumour antigens, which were the finger-
prints left behind in human cancer. His achievements include patents in field; discovery
of Respiratory Syncytial Virus in infant deaths in Naples and of tumor liberated protein
as a tumor associated antigen, 55 kilodalton protein overexpressed in lung tumors and
other epithelial adenocarcinomas.
e:
giuliotarro@gmail.com